BioNTech

Mainz, Germany Founded: 2008 • Age: 18 yrs
Immunotherapeutics for cancer and other diseases are developed.
Request Access

About BioNTech

BioNTech is a company based in Mainz (Germany) founded in 2008 by Christoph Huber and Ozlem Tureci.. BioNTech has raised $805.99 million across 12 funding rounds from investors including Fidelity Investments, Mirae Asset and Sanofi. The company has 6,770 employees as of December 31, 2024. BioNTech has completed 5 acquisitions, including Biotheus, CureVac and InstaDeep. BioNTech offers products and services including COMIRNATY and mRNA Cancer Immunotherapies. BioNTech operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Biogen, among others.

  • Headquarter Mainz, Germany
  • Employees 6770 as on 31 Dec, 2024
  • Founders Christoph Huber, Ozlem Tureci
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Biontech Se Sponsored Adr
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Health Technology & Digital Health
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $2.98 B
    -27.92
    as on Dec 31, 2024
  • Net Profit
    $-719.65 M
    -171.55
    as on Dec 31, 2024
  • EBITDA
    $-373.62 M
    -131.73
    as on Dec 31, 2024
  • Total Equity Funding
    $805.99 M (USD)

    in 12 rounds

  • Latest Funding Round
    $150 M (USD), Post-IPO

    Apr 14, 2022

  • Investors
  • Employee Count
    6770

    as on Dec 31, 2024

  • Investments & Acquisitions
    Biotheus

    & 4 more

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of BioNTech

BioNTech is a publicly listed company on the NASDAQ with ticker symbol BNTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: BNTX . Sector: Health technology · USA

Products & Services of BioNTech

BioNTech offers a comprehensive portfolio of products and services, including COMIRNATY and mRNA Cancer Immunotherapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

mRNA vaccine for preventing COVID-19 infections

Immunotherapies targeting cancer cells via mRNA technology

People of BioNTech
Headcount 1000-5000
Employee Profiles 455
Board Members and Advisors 6
Employee Profiles
People
Dirk Schreiber
SVP, Treasury
People
Oliver Ries
Director Quality / Qualified Person (qp)
People
Markus Dietz
Manager Quality Assurance
People
Anna Haas
Specialist Procurement Central & Specialty Lab Services

Unlock access to complete

Board Members and Advisors
people
Anja Morawietz
Director
people
Rudolf Staudigl
Director

Unlock access to complete

Funding Insights of BioNTech

BioNTech has successfully raised a total of $805.99M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $150 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 12
  • Last Round Post-IPO — $150.0M
  • First Round
  • Investors Count 19
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2022 Amount Post-IPO - BioNTech Valuation

investors

Sep, 2020 Amount Post-IPO - BioNTech Valuation

investors

Jun, 2020 Amount Post-IPO - BioNTech Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in BioNTech

BioNTech has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Mirae Asset and Sanofi. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
An investment platform is provided for diverse sectors and geographies.
Founded Year Domain Location
Jebsen Capital is engaged in multi-strategy investments for Jebsen Group.
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by BioNTech

BioNTech has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Biotheus, CureVac and InstaDeep. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Developer of antibody-based therapeutics for cancer treatment
2018
Alternatives to antibiotics are developed via phage therapy expertise.
2016
AI and cloud-based automation solutions are provided for organizational optimization.
2015
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - BioNTech

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Biontech Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of BioNTech

BioNTech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Biogen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Targeted and immune-oncology drugs for cancer treatment are developed.
domain founded_year HQ Location
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
domain founded_year HQ Location
Therapies for neurodegenerative and immunology disorders are developed.
domain founded_year HQ Location
Small molecules are developed for cancer and skin disease treatments.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Biontech

Frequently Asked Questions about BioNTech

When was BioNTech founded?

BioNTech was founded in 2008.

Where is BioNTech located?

BioNTech is headquartered in Mainz, Germany. It is registered at Mainz, Rhineland-palatinate, Germany.

Is BioNTech a funded company?

BioNTech is a funded company, having raised a total of $805.99M across 12 funding rounds to date. The company's 1st funding round was a Post-IPO of $250M, raised on Jun 01, 2008.

How many employees does BioNTech have?

As of Dec 31, 2024, the latest employee count at BioNTech is 6,770.

What is the annual revenue of BioNTech?

Annual revenue of BioNTech is $2.98B as on Dec 31, 2024.

What does BioNTech do?

BioNTech was established in 2008 in Mainz, Germany, within the biotechnology sector. Immunotherapeutics targeting cancer and additional diseases are developed, with an oncology pipeline encompassing mRNA-based treatments, modified cell therapies, antibodies, and small molecule immunomodulators. Optimization for specific action mechanisms, precise targeting, potency, and efficacy is emphasized in these efforts. Operations center on advancing therapeutic innovations for clinical applications.

Who are the top competitors of BioNTech?

BioNTech's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.

What products or services does BioNTech offer?

BioNTech offers COMIRNATY and mRNA Cancer Immunotherapies.

Is BioNTech publicly traded?

Yes, BioNTech is publicly traded on NASDAQ under the ticker symbol BNTX.

How many acquisitions has BioNTech made?

BioNTech has made 5 acquisitions, including Biotheus, CureVac, and InstaDeep.

Who are BioNTech's investors?

BioNTech has 19 investors. Key investors include Fidelity Investments, Mirae Asset, Sanofi, Fosun Pharmaceutical, and Gates Foundation.

What is BioNTech's ticker symbol?

The ticker symbol of BioNTech is BNTX on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available